Florian D. Vogl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Florian D. Vogl has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Agatha Eisendle
Institute of Genetic Medicine, European Academy, Bolzano, Italy
1 shared publication - Alessandro De Grandi
Institute of Genetic Medicine, European Academy, Bolzano, Italy
1 shared publication - Alice Riegler
Institute of Genetic Medicine, European Academy, Bolzano, Italy
1 shared publication - Christian Fuchsberger
Institute for Biomedicine, Eurac Research, Bolzano, Italy
1 shared publication - Christian Josef Wiedermann
Institute of General Practice and Public Health, Claudiana—College of Health Professions, 39100 Bolzano, Italy
1 shared publication - Claudia B Volpato
Institute of Genetic Medicine, European Academy, Bolzano, Italy
1 shared publication
Latest Publications
- Open Access
- 5 June 2007
- Published by Springer Nature in BMC Medical Genetics
- Vol. 8 (1) , 29
The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives
There is increasing evidence of the important role that small, isolated populations could play in finding genes involved in the etiology of diseases. For historical and political reasons, South Tyrol, the northern most Italian region, includes several villages of small dimensions which remained isolated over the centuries.
- 5 June 2007
- Published by Springer Nature in BMC Medical Genetics
- Vol. 8 (1) , 29
Open AccessThe genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives
There is increasing evidence of the important role that small, isolated populations could play in finding genes involved in the etiology of diseases. For historical and political reasons, South Tyrol, the northern most Italian region, includes several villages of small dimensions which remained isolated over the centuries.
- 19 October 2006
- Published by Springer Nature in Familial Cancer
- Vol. 6 (1) , 63-71
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred
Germline mutations in the BRCA1 gene are associated with an increased risk of breast and ovarian cancer, but there is controversy about the true magnitude of these risks. Observed differences can arise from several sources, both genetic and methodological. To examine the efficiency and bias associated with different methods of risk calculation, we analyzed a single mutation in a large pedigree with known ascertainment. Age-specific penetrance of breast and ovarian cancer was estimated using the Kaplan–Meier method and two likelihood-based approaches [maximum likelihood estimation, maximization of the logarithm of the odds (LOD) score]. Excess risk of other cancers due to the BRCA1 mutation was assessed. The estimated risk of breast and ovarian cancer at age 70 was 0.80 using the Kaplan–Meier approach and 0.55 using the maximum likelihood method. Both likelihood-based methods yielded similar results for the combined breast/ovarian phenotype, but using the maximum LOD score method lower estimates were obtained if only cancer at one site was considered. In the examined family, a high risk of ovarian cancer was found which might be an effect of the central location of the mutation within BRCA1. The risk of cancer at other sites than breast and ovaries was significantly elevated, but it was not possible to identify a single cancer site that could be said to be associated with the BRCA1 mutation. Estimating the penetrance of a specific mutation using different approaches, we found that both the choice of study population and statistical method affect the magnitude of the estimates.
- 19 October 2006
- Published by Springer Nature in Familial Cancer
- Vol. 6 (1) , 63-71
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred
Germline mutations in the BRCA1 gene are associated with an increased risk of breast and ovarian cancer, but there is controversy about the true magnitude of these risks. Observed differences can arise from several sources, both genetic and methodological. To examine the efficiency and bias associated with different methods of risk calculation, we analyzed a single mutation in a large pedigree with known ascertainment. Age-specific penetrance of breast and ovarian cancer was estimated using the Kaplan–Meier method and two likelihood-based approaches [maximum likelihood estimation, maximization of the logarithm of the odds (LOD) score]. Excess risk of other cancers due to the BRCA1 mutation was assessed. The estimated risk of breast and ovarian cancer at age 70 was 0.80 using the Kaplan–Meier approach and 0.55 using the maximum likelihood method. Both likelihood-based methods yielded similar results for the combined breast/ovarian phenotype, but using the maximum LOD score method lower estimates were obtained if only cancer at one site was considered. In the examined family, a high risk of ovarian cancer was found which might be an effect of the central location of the mutation within BRCA1. The risk of cancer at other sites than breast and ovaries was significantly elevated, but it was not possible to identify a single cancer site that could be said to be associated with the BRCA1 mutation. Estimating the penetrance of a specific mutation using different approaches, we found that both the choice of study population and statistical method affect the magnitude of the estimates.
- Open Access
- 1 November 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (11) , 5307-5312
Increased Risk for Nonmedullary Thyroid Cancer in the First Degree Relatives of Prevalent Cases of Nonmedullary Thyroid Cancer: A Hospital-Based Study
The genetic basis for nonmedullary forms of thyroid cancer (NMTC) is less well established than that of medullary thyroid cancer. However, epidemiological and family studies suggest that a proportion of NMTC may be due to inherited predisposition. To estimate the familial risk of thyroid cancer, we conducted a hospital-based case-control study at the Princess Margaret Hospital in Toronto, Ontario, Canada, and at 2 university hospitals in Montréal, Québec, Canada. We obtained pedigrees from 339 unselected patients diagnosed with NMTC and from 319 unaffected ethnically matched controls. Family histories of cancer were obtained from the cases and controls for 3292 first degree relatives of cases and controls. Seventeen cases (5.0%) and 2 controls (0.6%) reported at least one first degree relative with thyroid cancer. In relatives of patients with thyroid cancer, the incidence of any type of cancer (including NMTC) was 38% higher than in relatives of controls (incidence rate ratio, 1.4; 95% confidence interval, 1.1–1.7). The relative risk for thyroid cancer was 10-fold higher in relatives of cancer patients than in controls (incidence rate ratio, 10.3; 95% confidence interval, 2.2–47.6). Our findings suggest that hereditary or other familial factors are important in a small proportion of NMTC. Molecular studies are needed to determine the genetic basis of cancer susceptibility in these families.
- 1 November 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (11) , 5307-5312
Open AccessIncreased Risk for Nonmedullary Thyroid Cancer in the First Degree Relatives of Prevalent Cases of Nonmedullary Thyroid Cancer: A Hospital-Based Study
The genetic basis for nonmedullary forms of thyroid cancer (NMTC) is less well established than that of medullary thyroid cancer. However, epidemiological and family studies suggest that a proportion of NMTC may be due to inherited predisposition. To estimate the familial risk of thyroid cancer, we conducted a hospital-based case-control study at the Princess Margaret Hospital in Toronto, Ontario, Canada, and at 2 university hospitals in Montréal, Québec, Canada. We obtained pedigrees from 339 unselected patients diagnosed with NMTC and from 319 unaffected ethnically matched controls. Family histories of cancer were obtained from the cases and controls for 3292 first degree relatives of cases and controls. Seventeen cases (5.0%) and 2 controls (0.6%) reported at least one first degree relative with thyroid cancer. In relatives of patients with thyroid cancer, the incidence of any type of cancer (including NMTC) was 38% higher than in relatives of controls (incidence rate ratio, 1.4; 95% confidence interval, 1.1–1.7). The relative risk for thyroid cancer was 10-fold higher in relatives of cancer patients than in controls (incidence rate ratio, 10.3; 95% confidence interval, 2.2–47.6). Our findings suggest that hereditary or other familial factors are important in a small proportion of NMTC. Molecular studies are needed to determine the genetic basis of cancer susceptibility in these families.